GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akouos Inc (NAS:AKUS) » Definitions » Earnings Yield (Joel Greenblatt) %

Akouos (Akouos) Earnings Yield (Joel Greenblatt) % : -80.65% (As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Akouos Earnings Yield (Joel Greenblatt) %?

Akouos's Enterprise Value for the quarter that ended in Sep. 2022 was $115.71 Mil. Akouos's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-93.22 Mil. Akouos's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2022 was -80.65%.

The historical rank and industry rank for Akouos's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

AKUS' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -211593.67   Med: 0   Max: 1447239.96
Current: -26.11

During the past 4 years, the highest Earnings Yield (Joel Greenblatt) of Akouos was 1447239.96%. The lowest was -211593.67%. And the median was 0.00%.

AKUS's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -14.76 vs AKUS: -26.11

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Akouos's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2022 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Akouos Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Akouos's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akouos Earnings Yield (Joel Greenblatt) % Chart

Akouos Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Earnings Yield (Joel Greenblatt) %
- - -12.63 -97.09

Akouos Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.49 -97.09 625.00 -769.23 -80.65

Competitive Comparison of Akouos's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Akouos's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akouos's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akouos's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Akouos's Earnings Yield (Joel Greenblatt) % falls into.



Akouos Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Akouoss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2021 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-86.821/89.7594
=-96.73 %

Akouos's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-93.22 Mil.



Akouos  (NAS:AKUS) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Akouos Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Akouos's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Akouos (Akouos) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akouos Inc (NAS:AKUS) » Definitions » Earnings Yield (Joel Greenblatt) %
Traded in Other Exchanges
N/A
Address
645 Summer Street, Suite 200, Boston, MA, USA, 02210
Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders.
Executives
Kearny Acquisition Corp 10 percent owner LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Lilly Eli & Co 10 percent owner LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Jennifer Anne Wellman officer: Chief Operating Officer C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
Sachiyo Minegishi officer: Chief Financial Officer C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
5am Ventures V, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Maha Katabi 10 percent owner SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Pivotal Bioventure Partners Fund I G.p., L.p. 10 percent owner 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Heather Preston director, 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102

Akouos (Akouos) Headlines

From GuruFocus